Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events

Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events

We collected 96 patients who received dual immunotherapy between January 2019 and June 2024, in a 1:1:1 ratio based on PD-L1 expression levels of negative (<1%), medium (1% ≤ PD-L1 ≤ 49%), and high (PD-L1 ≥ 50%). This study evaluates the efficacy and safety of dual immunotherapy in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Luan, Jianqing Hao, Xiaohong Xie, Xinqing Lin, Shuaiying Wang, Baodan Yu, Qingqing Yang, Changchun Wang, Yang Luan, Gang Yang, Hanxiu Lu, Ping Sun, Yunhui Zhang, Nanshan Zhong, Chengzhi Zhou
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Dual immunotherapy
immune-related adverse events
survival period
treatment efficacy
immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2542068
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We collected 96 patients who received dual immunotherapy between January 2019 and June 2024, in a 1:1:1 ratio based on PD-L1 expression levels of negative (<1%), medium (1% ≤ PD-L1 ≤ 49%), and high (PD-L1 ≥ 50%). This study evaluates the efficacy and safety of dual immunotherapy in patients with advanced NSCLC, stratified by PD-L1 expression levels. Among the 96 patients, the objective response rate (ORR) was 37.5%, disease control rate (DCR) was 67.8%. In the multivariate analysis of PFS, PD-L1 ≥ 50% (HR = 0.40, 95% CI: 0.22–0.74) was identified as a protective factor for PFS, while PS Score ≥ 2 (HR = 2.74, 95% CI: 1.11–6.77) and stage IV tumors (HR = 2.05, 95% CI: 1.02–4.12) were risk factors. In the multivariate analysis of OS, PD-L1 between 1% and 49% (HR = 0.51, 95% CI: 0.28–0.90) and PD-L1 ≥ 50% (HR = 0.31, 95% CI: 0.17–0.57) were protective factors, with no risk factors detected. The incidence of adverse events was 77.1%, with a 34.3% incidence of grade 3–4 immune-related adverse events. And PD-L1 ≥ 50% group adverse events incidence more common, with an overall incidence of 87.5% and a grade 3–4 incidence of 40.6%. Patients with high PD-L1 expression (≥50%) demonstrated improved progression-free survival (PFS, HR = 0.40) and overall survival (OS, HR = 0.31) but experienced a higher incidence of severe adverse events (40.6%).
ISSN:2164-5515
2164-554X

Similar Items